A Computational Approach to Identify Novel Protein Targets Uncovers New Potential Mechanisms of Action of Mirtazapine S (+) and R (−) Enantiomers in Rett Syndrome
Open Access
- 26 May 2025
- journal article
- Published by Wiley in Journal of Neurochemistry
- Vol. 169 (5) , e70093
Abstract
Rett syndrome (RTT) is a progressive neurodevelopmental disorder that affects approximately 1:10000 newborn girls and is primarily caused by mutations in the X‐linked gene MECP2 . Due to reduced brain monoamine levels in RTT, antidepressants have been explored as potential therapies. In previous studies, we demonstrated that the antidepressant mirtazapine (MTZ) alleviates symptoms in Mecp2 ‐mutant mice and RTT adult patients. However, the mechanism of action of MTZ, a racemic mixture that binds to multiple receptors, remains unclear. This study introduces a computational approach to screen the “human pocketome,” comprising over 25 K ligand‐bound pockets derived from more than 210 K human protein structures available in the RCSB Protein Data Bank, aiming to identify binding pockets with high affinity for each MTZ enantiomer. Novelty concerns the approach to compare the two enantiomers of MTZ to other drugs experimentally determined as inactive for RTT. This approach introduces a new metric, the ZZscore, which ranks tested proteins and pockets based on their degree of interaction with the tested drugs. This enables the identification of potential drug‐protein interactions relevant to the disease and/or phenotypic traits under study. Initial relaxed settings and thresholds parameters suggested over 30 potential targets, among which the RASH/SOS1 complex, but in vitro experiments on cultured hippocampal neurons from Mecp2 ‐KO mice excluded any MTZ effect on it. Thus, we refined the procedure with more stringent parameters and identified 16 protein targets for S (+)MTZ and 14 for R (−)MTZ, with 5 common targets. Pathway enrichment analysis revealed 25 pathways for S (+)MTZ and 24 for R (−)MTZ, with 11 common pathways, many related to MeCP2 functions disrupted in RTT, such as epigenetic chromatin regulation, intracellular signaling, energy metabolism, cholesterol and lipid metabolism, and catecholamine biosynthesis. Overall, the presented computational modeling strategy for target identification allowed us to hypothesize new mechanisms of action for the two MTZ enantiomers. imageKeywords
Funding Information
- Fondation Jérôme Lejeune
This publication has 118 references indexed in Scilit:
- The Protein Data BankNucleic Acids Research, 2000
- Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2Nature Genetics, 1999
- Mirtazapine: a newer antidepressant.1999
- Decreased Dendritic Branching in Frontal, Motor and Limbic Cortex in Rett Syndrome Compared with Trisomy 21Journal of Neuropathology & Experimental Neurology, 1998
- Distribution of mRNAs Encoding the Peroxisome Proliferator‐Activated Receptor α, β, and γ and the Retinoid X Receptor α, β, and γ in Rat Central Nervous SystemJournal of Neurochemistry, 1998
- Mirtazapine versus amitriptyline in the long-term treatment of depressionInternational Clinical Psychopharmacology, 1998
- Drug interactions--friend or foe?1998
- MirtazapineJournal of Clinical Psychopharmacology, 1997
- Morphological study of neocortical areas in Rett syndromeActa Neuropathologica, 1997
- Selective Dendritic Alterations in the Cortex of Rett SyndromeJournal of Neuropathology & Experimental Neurology, 1995